Perspective Therapeutics CATX
NYSE CATX
$2.98 -0.14 (-4.49%)
As of: Sep 9, 2026 · 3:59 PM EDT

Perspective Therapeutics (CATX) Goodwill (2023 - 2024)

Perspective Therapeutics' (CATX) quarterly Goodwill came in at $24.1 million in Q3 2024, down 11.78% year-over-year from $27.3 million in Q4 2023, and little changed quarter-over-quarter from $24.1 million in Q2 2024.

Analysis

Perspective Therapeutics (CATX) Goodwill (2023 - 2024) Analysis & Trends

Perspective Therapeutics has disclosed Goodwill across 2 years of filings, most recently posting $24.1 million for Q3 2024.

  • In Q3 2024, Goodwill fell 11.78% year-over-year to $24.1 million; the TTM figure through Sep 2024 stood at $24.1 million (down 11.78% YoY), while the FY2023 annual figure was $24.1 million, changed N/A from the prior year.
  • Goodwill came in at $24.1 million for Q3 2024 at Perspective Therapeutics, roughly flat from $24.1 million in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $27.3 million in Q1 2023 to a low of $24.1 million in Q4 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn
10 Perspective Therapeutics 361.95 Mn 361.95 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2024 24.10 Mn
Jun 30, 2024 24.10 Mn
Mar 31, 2024 24.10 Mn
Dec 31, 2023 24.10 Mn
Sep 30, 2023 27.32 Mn
Jun 30, 2023 27.32 Mn
Mar 31, 2023 27.32 Mn